Table 1.

Comparison of MYD88 L265P before and after treatment using real-time AS-PCR in patients with WM

Patient	Age (years)	Gender	Treatment	Pre-/posttherapy BM involved, %	Pre-/posttherapy MYD88 L265P levels	Change in BM involved, %	Change in MYD88 L265P levels, %
A	61	Male	Benda-R	70 (negative)	78.45 (negative)	−100	−100
B	44	Male	R-CD	90	60.73	−89	−96.33
				10	2.23
C	52	Male	R-CD	50	72.12	−90	−73.61
				5	19.03
D	59	Male	Everolimus	95	99.15	−47	−45.39
				50	54.15
E	63	Male	Everolimus	90	96.07	−67	−21.03
				30	75.87
F	70	Male	Everolimus	95	95.93	−37	−8.61
				60	87.67
G	63	Male	Everolimus	20	67.93	25	12.87
				25	76.67

Changes in expression levels for MYD88 L265P were calculated from a standard curve.

Benda-R, bendamustine and rituximab; R-CD, rituximab, cyclophosphamide, and dexamethasone.